Free tool
FAERS Monitor: Rizafilm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205394 or its brand name (Rizafilm, Rizatriptan Benzoate). Reports on generic versions are filed under their own applications.
Reports
1,646
Serious
1,034
63% of reports
Hospitalization
358
Death reported
34
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective420
- headache259
- off label use247
- nausea239
- migraine204
- product use in unapproved indication178
- drug intolerance175
- hypersensitivity169
- fatigue140
- swelling face132
- angioedema128
- dysphonia128
- swollen tongue128
- drug ineffective for unapproved indication121
- diarrhoea107
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 7 |
| 2006 | 3 |
| 2007 | 21 |
| 2008 | 31 |
| 2009 | 28 |
| 2010 | 15 |
| 2011 | 20 |
| 2012 | 15 |
| 2013 | 42 |
| 2014 | 36 |
| 2015 | 32 |
| 2016 | 65 |
| 2017 | 61 |
| 2018 | 96 |
| 2019 | 131 |
| 2020 | 113 |
| 2021 | 118 |
| 2022 | 159 |
| 2023 | 152 |
| 2024 | 166 |
| 2025 | 189 |
| 2026 | 142 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,513 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| swollen tongueSignal | 128 | 52.6 | 44.5 | 6,408 |
| angioedemaSignal | 128 | 37.1 | 31.4 | 4,454 |
| drug ineffective for unapproved indicationSignal | 121 | 28.2 | 23.8 | 3,153 |
| dysphoniaSignal | 128 | 28.0 | 23.7 | 3,310 |
| migraineSignal | 204 | 27.4 | 24.1 | 5,168 |
| swelling faceSignal | 132 | 26.0 | 22.0 | 3,146 |
| drug intoleranceSignal | 175 | 23.2 | 20.2 | 3,704 |
| hypersensitivitySignal | 169 | 11.6 | 10.1 | 1,647 |
| product use in unapproved indicationSignal | 178 | 9.2 | 8.0 | 1,304 |
| headacheSignal | 259 | 5.3 | 4.7 | 922 |
| drug ineffectiveSignal | 420 | 4.1 | 3.8 | 1,035 |
| nauseaSignal | 239 | 3.9 | 3.4 | 523 |
| off label useSignal | 247 | 3.6 | 3.2 | 482 |
| fatigueSignal | 140 | 2.3 | 2.0 | 105 |
| diarrhoeaSignal | 107 | 2.1 | 1.8 | 64 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.